News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts
Jaguar Health's crofelemer, the only oral drug approved under FDA's Botanical Guidance, shows promising results in rare disease and cancer therapy-related diarrhea programs. Expected Q2-Q4 2025 catalysts discussed -
-
-
COMMUNIQUÉ DE PRESSE
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease
Jaguar Health's crofelemer shows promise in reducing TPN needs for MVID and SBS-IF patients. Investor webcast to review proof-of-concept study results presented at ELITE PED-GI Congress -
-
-
COMMUNIQUÉ DE PRESSE
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Jaguar Health investor webcast to review crofelemer impact on MVID and SBS-IF patients. No approved treatments for MVID, study presented by Dr. Miqdady at ELITE PED-GI Congress -
